Drug Trial News

RSS

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

Tiotropium delivered once daily via Respimat significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS/LABA, irrespective of their allergic status.

24 Feb 2013

New leprosy test, experimental vaccine might hasten disease elimination, Slate reports

Slate examines a new rapid diagnostic test and an experimental vaccine for leprosy, both developed by the Infectious Disease Research Institute in Seattle, writing, "The two tools together could finally free humans from the vicious cycle of a disease that has afflicted the population for at least 4,000 years."

22 Feb 2013

NIAID-funded Phase I trial to evaluate two related candidate vaccines against shigellosis

Researchers have launched an early-stage human clinical trial of two related candidate vaccines to prevent infection with Shigella, bacteria that are a significant cause of diarrheal illness, particularly among children.

21 Feb 2013

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.

21 Feb 2013

Dabigatran decreases risk of recurrent venous thromboembolism

New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).

21 Feb 2013

Outcomes no better with epidural steroids for patients with spinal stenosis

For patients with spinal stenosis, epidural steroid injections (ESI) may actually lead to worse outcomes-whether or not the patient later undergoes surgery, according to a study in the February 15 issue of Spine. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

19 Feb 2013

Positive results from Neurim’s Piromelatine phase II study on insomnia

Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia.

18 Feb 2013

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).

16 Feb 2013

MSU to launch levetiracetam clinical trial for treatment of African children with epilepsy

Determined to bring relief to seizure victims, a Michigan State University research team this month begins a groundbreaking clinical drug trial that could help prevent a quarter-million African children from developing epilepsy each year.

16 Feb 2013

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Genzyme, a Sanofi company, today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1.

15 Feb 2013

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the extension of its phase II clinical trial with Validive in the United States in radio/chemotherapy-induced oral mucositis prevention in patients with head and neck cancer.

15 Feb 2013

New progestogen-only treatment effective in stopping acute abnormal uterine bleeding

New research from the Los Angeles Biomedical Research Institute (LA BioMed) found a progestogen-only treatment halted bleeding in women suffering from extremely heavy periods, according to the study published online by the American Journal of Obstetrics and Gynecology.

15 Feb 2013

Selumetinib shrinks tumors in women with low-grade ovarian cancer

Researchers at The University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix have discovered that many women with low-grade serous carcinoma of the ovary or peritoneum have seen their tumors stabilize or shrink after taking a regular dose of the compound selumetinib.

15 Feb 2013

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain for reasons no one previously has understood. Now, Mayo Clinic researchers have found out why this happens.

15 Feb 2013

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).

15 Feb 2013

Probiotics shows promise in reducing both incidence and severity of necrotizing enterocolitis

"Good" bacteria that live in our intestines have been linked with a variety of health benefits, from fighting disease to preventing obesity. In a new study, Kriston Ganguli of Massachusetts General Hospital for Children and Harvard Medical School and her colleagues have discovered another advantage to these friendly microscopic tenants: Chemicals secreted by good bacteria that typically live in the intestines of babies could reduce the frequency and severity of a common and often-lethal disease of premature infants.

14 Feb 2013

IAP antagonists may actually increase risk of bone tumors

Cancer drugs should kill tumors, not encourage their spread. But new evidence suggests that an otherwise promising class of drugs may actually increase the risk of tumors spreading to bone, according to researchers at Washington University School of Medicine in St. Louis.

14 Feb 2013

GSK1322322 targets gram-positive bacteria including methicillin-resistant strains of MRSA

An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.

14 Feb 2013

Traumatic brain injury investigational treatment from BHR Pharma receives EMA orphan medicinal product designation

BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.

14 Feb 2013

Updated Cochrane review on vitamin C and common cold

According to an updated Cochrane review on vitamin C and the common cold, vitamin C seems to be particularly beneficial for people under heavy physical stress. In five randomized trials of participants with heavy short-term physical stress, vitamin C halved the incidence of the common cold.

14 Feb 2013

Drug Trial News

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

New leprosy test, experimental vaccine might hasten disease elimination, Slate reports

NIAID-funded Phase I trial to evaluate two related candidate vaccines against shigellosis

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Dabigatran decreases risk of recurrent venous thromboembolism

Outcomes no better with epidural steroids for patients with spinal stenosis

Positive results from Neurim’s Piromelatine phase II study on insomnia

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

MSU to launch levetiracetam clinical trial for treatment of African children with epilepsy

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

New progestogen-only treatment effective in stopping acute abnormal uterine bleeding

Selumetinib shrinks tumors in women with low-grade ovarian cancer

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Probiotics shows promise in reducing both incidence and severity of necrotizing enterocolitis

IAP antagonists may actually increase risk of bone tumors

GSK1322322 targets gram-positive bacteria including methicillin-resistant strains of MRSA

Traumatic brain injury investigational treatment from BHR Pharma receives EMA orphan medicinal product designation

Updated Cochrane review on vitamin C and common cold

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News